You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Popup

Report an adverse Event

Stay informed

Central Nervous System at GSK

Find out more about our CNS portfolio.

Our Buspar product

Buspar is the first non-benzodiazepine anxiolytic agent to be introduced in medical practice. It is indicated in short term management of anxiety disorders, relief of symptoms of anxiety with or without symptoms of depression.

Learn more about our Buspar product

Related Resources

  1. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
  2. https://www.appi.org › american_ps...APA - American Psychiatric Association Practice Guideline for the Treatment of Patients With ...
  3. https://www.canmat.org › 2019/03/272018 Bipolar Guidelines - Resources | CANMAT
  4. https://www.aan.com › GuidelinesWeb result with site linksGuidelines - American Academy of Neurology
  5. https://www.nice.org.uk › guidanceWeb resultsEpilepsy | Topic | NICE
  6. https://www.sign.ac.uk › sign-143-d...Web resultsSIGN 143 Diagnosis and management of epilepsy in adults - Scottish Intercollegiate

Trademarks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.